Peramivir is an intravenous anti-influenza agent that inhibits viral growth by selectively inhibiting neuraminidase in human influenza A and B virus. To characterize its pharmacokinetics, population pharmacokinetic analysis of peramivir was performed using 3199 plasma concentration data samples from 332 subjects in six clinical studies in Japan and the US, including studies with renal impairment subjects, elderly subjects and influenza patients. A three-compartment model well described the plasma concentration data of peramivir, and creatinine clearance was found to be the most important factor influencing clearance. Age and body weight were also found to be covariates for clearance and volume of distribution, respectively. No pharmacokinetic difference was found between genders or between Japanese and US subjects.

 

(후략)